Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

174
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
174
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

187
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
187
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nonparametric testing methods based on relative effect in non-inferiority clinical trial with multiple experimental drugs.

Journal of biopharmaceutical statistics·2026
Same author

Selective and direct hydrogen generation from mixed plastic waste via alkaline thermal treatment with inherent carbon storage.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Luteolin from Lonicera japonica Thunb. restores GLUT4-mediated glucose uptake via PI3K/Akt signaling in insulin resistance.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Peripheral immune profiling identifies CD8⁺ T<sub>EMRA</sub> and CD4⁺ T TIGIT⁺ cells as independent prognostic markers for first-line immune checkpoint inhibitors in advanced non-small cell lung cancer.

Respiratory research·2026
Same author

Molecular prevalence, genomic characterization, and zoonotic potential of novel paramyxovirus and hepacivirus in Alexandromys fortis, Republic of Korea.

Veterinary research·2026
Same author

A Landmark-Guided Dual-Stream Synergistic Framework for Automated Intracranial Aneurysm Detection in Magnetic Resonance Angiography.

Journal of imaging informatics in medicine·2026

Related Experiment Video

Updated: Jul 9, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K

Review of Current Treatment Intensification Strategies for Prostate Cancer Patients.

Sobia Wasim1, Jieun Park2, Seungyoon Nam3

  • 1Department of Biochemistry, College of Medicine, Gachon University, Incheon 21999, Republic of Korea.

Cancers
|December 9, 2023
PubMed
Summary

Treatment intensification (TI) combines radiotherapy and hormonal therapy for prostate cancer (PCa), showing reduced mortality and improved survival. Further research is needed to confirm the efficacy of this advanced PCa treatment.

Keywords:
ADTLHRH agonistprostate cancerradiotherapy/radiation therapytreatment intensification

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.4K
Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

7.9K

Related Experiment Videos

Last Updated: Jul 9, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.4K
Focal Laser Ablation of Prostate Cancer: An Office Procedure
11:07

Focal Laser Ablation of Prostate Cancer: An Office Procedure

Published on: March 30, 2021

7.9K

Area of Science:

  • Oncology
  • Urology
  • Medical treatment

Background:

  • Prostate cancer (PCa) was historically treated solely with surgery.
  • The introduction of luteinizing hormone-releasing hormone (LHRH) agonists in the 1980s revolutionized PCa treatment.
  • Combined therapies like androgen deprivation therapy (ADT), chemotherapy, and radiotherapy became standard.

Purpose of the Study:

  • To review the latest outcome results of pivotal trials and clinical studies on treatment intensification (TI) for prostate cancer.
  • To highlight the efficacy of combined modality treatments in managing localized or locally advanced PCa.

Main Methods:

  • Review of pivotal trials and clinical studies.
  • Analysis of outcome data for combined modality treatments, specifically treatment intensification (TI).

Main Results:

  • Combined modality treatments, including TI, have demonstrated a reduction in disease-specific mortality.
  • Improved overall survival rates have been observed with these intensified treatment strategies.
  • TI involves the combined use of radiotherapy (RT) and hormonal or drug treatments for PCa.

Conclusions:

  • Treatment intensification (TI) shows promise for localized or locally advanced prostate cancer.
  • Current data suggest TI can reduce mortality and improve survival.
  • Further research is warranted to definitively confirm the efficacy of TI in prostate cancer management.